FrancophonIA/ELRC3.0 huggingface dataset:
English: The reconstituted Xiapex solution can be kept at room temperature (20º to 25ºC) for up to one hour or refrigerated at 2º to 8°C for up to 4 hours prior to administration.
Croatian: Rekonstituirana otopina Xiapexa može se čuvati na sobnoj temperaturi (20º do 25ºC) najviše jedan sat ili u hladnjaku na 2° do 8°C najviše 4 sata prije primjene.
English: The solution should visually be inspected for particulate matter and discoloration prior to administration.
Croatian: Prije primjene otopinu treba vizualno pregledati da ne sadrži čestice i da nije promijenila boju.
English: d) Using a 1 ml syringe with 0.01 ml graduations with a 27-gauge 12-13 mm needle (not supplied), withdraw the correct volume of the diluent supplied:
Croatian: d) Pomoću nove štrcaljke bez mrtvog volumena s oznakama na svakih 0,01 ml s trajno pričvršćenom iglom promjera 27 G i duljine 12 ili 13 mm (nije priložena), izvucite volumen od
English: ANNEX III LABELLING AND PACKAGE LEAFLET
Croatian: Demografska obilježja i obilježja na početku ispitivanja
English: • Not to attempt to disrupt the injected cord by self-manipulation at any time.
Croatian: • Da nikad ne pokušavaju sami raskinuti tračak nakon injekcije.
English: 0.9 mg of collagenase clostridium histolyticum.
Croatian: Jedna bočica Xiapexa sadrži 0,9 mg kolagenaze clostridium histolyticum.
English: Musculoskeletal discomfort or stiffness, joint stiffness or crepitation Limb discomfort Tendonitis Muscle spasms or weakness
Croatian: Poremećaji mišićno koštanog sustava i vezivnog tkiva bol u leđima, pubičnoj regiji ili preponama poremećaj ligamenata bol u ligamentima mišićno-koštana nelagoda
English: and injection site oedema.
Croatian: osteopeniju ili osteoporozu.
English: Discard the syringe and needle used for reconstitution and the diluent vial.
Croatian: Štrcaljku i iglu koje ste upotrijebili za rekonstituciju te bočicu od otapala bacite.
English: • dizziness
Croatian: • koprivnjaču
English: • painful erection, painful sex and erectile dysfunction.
Croatian: • bolna erekcija, bolan spolni odnos i erektilna disfunkcija Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba):
English: The white lyophilized powder is supplied in a 3 ml type I clear glass vial with rubber stopper, aluminium seal and flip-off plastic cap.
Croatian: Bijeli liofilizirani prašak isporučuje se u bočici od prozirnog stakla tipa
English: Reproductive system and breast disorders
Croatian: Poremećaji reproduktivnog sustava i dojki hematom penisaa,
English: The company withdrew the application on 29 October 2019.
Croatian: Tvrtka je povukla zahtjev 29. listopada 2019.
English: In addition, more data were needed to show that the quality of the medicine is consistent.
Croatian: Osim toga, bilo je potrebno više podataka koji bi dokazali da je kvaliteta lijeka dosljedna.
English: 15 November 2019 EMA/610519/2019 EMEA/H/C/004394
Croatian: EMA/610519/2019 EMEA/H/C/004394
English: How does Linhaliq work?
Croatian: Kako djeluje Linhaliq?
English: The Agency considered that the two studies presented did not show convincingly that the medicine was effective.
Croatian: Agencija je smatrala da dva predstavljena ispitivanja nisu uvjerljivo dokazala da je lijek učinkovit.
English: What is Linhaliq and what was it intended to be used for?
Croatian: Što je Linhaliq i za što se trebao koristiti?
English: This was intended to slow down the medicine's release into the lungs, allowing it to act for longer.
Croatian: Time se trebalo usporiti oslobađanje lijeka u pluća, omogućavajući mu da djeluje duže.
English: What did the Agency recommend at that time?
Croatian: Koja je bila preporuka Agencije u tom trenutku?
English: The application was withdrawn after that the European Medicines Agency had evaluated the information from the company and prepared questions for the company.
Croatian: Zahtjev je povučen nakon što je Europska agencija za lijekove procijenila informacije koje je tvrtka dostavila i sastavila pitanja za tvrtku.
English: Does this withdrawal affect patients in clinical trials or compassionate use programmes?
Croatian: Ima li ovo povlačenje zahtjeva posljedice za bolesnike u kliničkim ispitivanjima ili u programima milosrdnog davanja lijekova?
English: As a result, bacteria cannot multiply and they die.
Croatian: Kao rezultat toga, bakterije se ne mogu umnožavati i odumiru.
English: The company had responded to the last round of questions, and the Agency was completing its assessment of the responses at the time of the withdrawal.
Croatian: Tvrtka je odgovorila na posljednji niz pitanja, a u trenutku povlačenja Agencija je dovršavala svoju procjenu odgovora.
English: The company presented the results of two studies in a total of 582 patients with non-cystic fibrosis bronchiectasis.
Croatian: Tvrtka je predstavila rezultate dvaju ispitivanja na ukupno 582 bolesnika s bronhiektazijama bez cistične fibroze.
English: Fluoroquinolones work by preventing bacteria from making copies of their DNA (genetic material).
Croatian: Fluorokinoloni djeluju tako što sprječavaju bakterije da stvaraju kopije svojeg DNK-a (genetskog materijala).
English: In its letter notifying the Agency of the withdrawal of the application, the company stated that it decided to withdraw its application because the data provided do not allow EMA's committee for human medicines to conclude on a positive benefit-risk balance for the medicine.
Croatian: U svojem dopisu kojim obavještava Agenciju o povlačenju zahtjeva, tvrtka je navela da je odlučila povući zahtjev jer dostavljeni podaci ne omogućavaju Odboru za lijekove za humanu uporabu pri agenciji EMA da donese pozitivan zaključak o omjeru koristi i rizika za lijek.
English: Linhaliq was developed for patients with ‘non-cystic fibrosis bronchiectasis', which means it was not intended for patients with bronchiectasis due to cystic fibrosis.
Croatian: Linhaliq je razvijen za bolesnike s „bronhiektazijama bez cistične fibroze”, što znači da nije bio namijenjen bolesnicima s bronhiektazijama uzrokovanima cističnom fibrozom.
English: The company informed the Agency that there are no ongoing clinical trials or compassionate use programmes with Linhaliq.
Croatian: Tvrtka je obavijestila Agenciju da nema kliničkih ispitivanja ili programa milosrdnog davanja lijeka Linhaliq koji su u tijeku.
English: The main measure of effectiveness was the time it took until patients had a flare-up of bronchiectasis.
Croatian: Glavno mjerilo učinkovitosti bilo je vrijeme koje je proteklo do pogoršanja simptoma bronhiektazija u bolesnika.
English: Withdrawal of application for the marketing authorisation of Linhaliq (ciprofloxacin)
Croatian: Povlačenje zahtjeva za izdavanje odobrenja za stavljanje u promet lijeka Linhaliq (ciprofloksacin)
English: In each study Linhaliq was compared with placebo (a dummy treatment).
Croatian: U svakom je ispitivanju lijek Linhaliq uspoređen s placebom (prividnim liječenjem).
English: Linhaliq contains the active substance ciprofloxacin and was to be available for inhalation using an inhaler device.
Croatian: Linhaliq sadrži djelatnu tvar ciprofloksacin i trebao je biti dostupan za inhalaciju s pomoću posebnog uređaja, inhalatora.
English: In Linhaliq, some of the active substance is enclosed in tiny fat particles called liposomes.
Croatian: U lijeku Linhaliq dio je djelatne tvari zatvoren u sitnim česticama masti koje se zovu liposomi.
English: The active substance in Linhaliq, ciprofloxacin, is an antibiotic belonging to a group called fluoroquinolones.
Croatian: Djelatna tvar u lijeku Linhaliq je ciprofloksacin, antibiotik koji pripada skupini naziva fluorokinoloni.
English: Therefore, at the time of the withdrawal, the Agency's opinion was that the benefits of Linhaliq did not outweigh its risks.
Croatian: Sukladno navedenome, Agencija je u vrijeme povlačenja smatrala kako koristi od lijeka Linhaliq ne nadmašuju s njim povezane rizike.
English: Based on the review of the data, at the time of the withdrawal, the Agency had several concerns and its provisional opinion was that Linhaliq could not have been authorised for treating or preventing flare-ups in adults with non-cystic fibrosis bronchiectasis who have long-term lung infection with Pseudomonas aeruginosa.
Croatian: Na temelju pregleda podataka, u trenutku povlačenja Agencija je smatrala da postoji nekoliko razloga za zabrinutost te je njezino privremeno mišljenje bilo da nije moguće dati odobrenje za Linhaliq za liječenje ili sprječavanje pogoršanja simptoma u odraslih osoba s bronhiektazijama bez cistične fibroze koje imaju dugotrajnu infekciju pluća bakterijom Pseudomonas aeruginosa.
English: Linhaliq was developed as a medicine for preventing and reducing exacerbations (flare-ups) of bronchiectasis in adults who have long-term lung infection with Pseudomonas aeruginosa bacteria.
Croatian: Linhaliq je razvijen kao lijek za sprječavanje i smanjenje egzacerbacija (pogoršanja simptoma) bronhiektazija u odraslih osoba koje imaju dugotrajnu infekciju pluća bakterijom Pseudomonas aeruginosa.
English: Aradigm Pharmaceuticals Limited withdrew its application for a marketing authorisation of Linhaliq for treating and preventing flare-ups of bronchiectasis in patients with long-term lung infection caused by Pseudomonas aeruginosa bacteria.
Croatian: Tvrtka Aradigm Pharmaceuticals Limited povukla je svoj zahtjev za izdavanje odobrenja za stavljanje u promet lijeka Linhaliq za liječenje i sprječavanje pogoršanja simptoma bronhiektazija u bolesnika s dugotrajnom infekcijom pluća uzrokovanom bakterijom Pseudomonas aeruginosa.
English: Bronchiectasis is a long-term condition in which the airways have widened and become flabby and scarred, with a build-up of mucus.
Croatian: Bronhiektazije su dugotrajno stanje pri kojem su se dišni putovi proširili te postaju mlohavi i puni ožiljaka, uz nakupljanje sluzi.
English: Withdrawal of application for the marketing authorisation of Linhaliq (ciprofloxacin) EMA/610519/2019
Croatian: (ciprofloksacin) EMA/610519/2019
English: The vaccine also contains ‘adjuvants' (aluminium hydroxide and saponin) to stimulate a better reaction by the immune system.
Croatian: Cjepivo također sadržava „adjuvans” (aluminijev hidroksid i saponin) kako bi se potaknula bolja reakcija imunosnog sustava.
English: The most common side effect with Bovilis Blue-8 (which may affect up to 1 in 10 animals) is an increase in body temperature between 0.5 and 1.0˚C that lasts no longer than one to two days.
Croatian: Najčešća nuspojava VMP-a Bovilis Blue-8 (koja se može javiti kod 1 od 10 životinja) jest porast tjelesne temperature od 0,5 do 1,0˚C u trajanju ne dužem od jednog do dva dana.
English: In the future, if the animals are exposed to the same type of bluetongue virus, the immune system will be able to produce antibodies more quickly.
Croatian: Kada životinje ubuduće budu izložene istom serotipu virusa bolesti plavog jezika, imunosni sustav brže će moći proizvesti protutijela.
English: The full EPAR for Bovilis Blue-8 can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Croatian: Cjeloviti EPAR za VMP Bovilis Blue-8 nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: The withdrawal period for meat and milk from cattle and sheep treated with Bovilis Blue-8 is ‘zero' days, which means there is no mandatory waiting time.
Croatian: Razdoblje karencije za meso i mlijeko goveda i ovaca liječenih VMP-om Bovilis Blue-8 iznosi „nula” dana, drugim riječima, nema obveznog perioda čekanja.
English: This medicine is the same as Bluevac BTV8, which is already authorised in the EU.
Croatian: Ovaj VMP isti je kao i VMP Bluevac BTV8, koji je već odobren u EU-u.
English: This authorisation was based on the authorisation granted to Bluevac BTV8 in 2011 (‘informed consent').
Croatian: Odobrenje se temeljilo na odobrenju danom za VMP Bluevac BTV8 2011. godine („informirani pristanak”).
English: The European Commission granted a marketing authorisation valid throughout the EU for Bovilis Blue-8 on 21 November 2017.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za VMP Bovilis Blue-8 na snazi u Europskoj uniji od 21/11/2017.
English: Bovilis Blue-8 contains a bluetongue virus that has been inactivated so that it cannot cause the disease.
Croatian: Bovilis Blue-8 sadržava virus bolesti plavog jezika koji je inaktiviran kako ne bi mogao uzrokovati bolest.
English: The Agency's Committee for Medicinal Products for Veterinary Use (CVMP) concluded that Bovilis Blue-8's benefits are greater than its risks and recommended that it be approved for use in the EU.
Croatian: Odbor za veterinarsko-medicinske proizvode (CVMP) pri Agenciji odlučio je da koristi od VMP-a Bovilis Blue-8 nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za primjenu u Europskoj uniji.
English: bluetongue virus vaccine, serotype 8 (inactivated)
Croatian: cjepivo s virusom plavog jezika, serotip 8 (inaktiviran)
English: Bovilis Blue-8 is a vaccine used in cattle and sheep to protect them against bluetongue disease, an infection caused by the bluetongue virus, which is transmitted by midges.
Croatian: Bovilis Blue-8 je cjepivo koje se primjenjuje u goveda i ovaca radi zaštite od bolesti plavog jezika, infekcije koju uzrokuje virus bolesti plavog jezika koji prenose mušice.
English: The company that makes Bluevac BTV8 has agreed that its scientific data can be used for Bovilis Blue-8 (‘informed consent').
Croatian: Proizvođač VMP-a Bluevac BTV8 pristao je da se njegovi znanstveni podatci koriste za VMP Bovilis Blue-8 (tzv. „informirani pristanak”).
English: Bovilis Blue-8 contains bluetongue viruses of one type (‘serotype 8').
Croatian: Bovilis Blue-8 sadržava viruse bolesti plavog jezika jednog serotipa („serotip 8”).
English: This is a summary of the European public assessment report (EPAR) for Bovilis Blue-8.
Croatian: Ovo je sažetak europskoga javnog izvješća o procjeni (EPAR) veterinarsko-medicinskog proizvoda Bovilis Blue-8.
English: The vaccine contains inactivated (killed) bluetongue virus, serotype 8.
Croatian: Cjepivo sadržava inaktivirani (umrtvljeni) virus bolesti plavog jezika, serotip 8.
English: For the full list of restrictions and all side effects reported with Bovilis Blue-8, see the package leaflet.
Croatian: Potpuni popis ograničenja i svih nuspojava zabilježenih pri primjeni VMP-a Bovilis Blue-8 potražite u uputi o VMP-u.
English: Bovilis Blue-8 is a vaccine.
Croatian: Bovilis Blue-8 je cjepivo.
English: It is not intended to provide practical advice on how to use Bovilis Blue-8.
Croatian: Svrha sažetka nije davati praktične savjete o primjeni VMP-a Bovilis Blue-8.
English: What is Bovilis Blue-8 and what is it used for?
Croatian: Što je Bovilis Blue-8 i za što se koristi?
English: For practical information about using Bovilis Blue-8, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Praktične informacije o primjeni VMP-a Bovilis Blue-8 vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno obratiti se svojem veterinaru ili ljekarniku.
English: What are the risks associated with Bovilis Blue-8?
Croatian: Koji su rizici povezani s VMP-om Bovilis Blue-8?
English: Why is Bovilis Blue-8 approved?
Croatian: Zašto je Bovilis Blue-8 odobren?
English: For more information about treatment with Bovilis Blue-8, animal owners or keepers should read the package leaflet or contact their veterinarian or pharmacist.
Croatian: Dodatne informacije o terapiji VMP-om Bovilis Blue-8 vlasnici životinja ili uzgajivači trebaju pročitati u uputi o VMP-u, odnosno obratiti se svojem veterinaru ili ljekarniku.
English: Other information about Bovilis Blue-8:
Croatian: Ostale informacije o VMP-u Bovilis Blue-8
English: How is Bovilis Blue-8 used?
Croatian: Kako se Bovilis Blue-8 koristi?
English: What benefits of Bovilis Blue-8 have been shown in studies?
Croatian: Koje su koristi od VMP-a Bovilis Blue-8 utvrđene u ispitivanjima?
English: How does Bovilis Blue-8 work?
Croatian: Kako djeluje Bovilis Blue-8?
English: It is available as tablets (50 mg).
Croatian: Dostupan je u obliku tableta (50 mg).
English: This summary was last updated in 05-2015.
Croatian: Sažetak je posljednji put ažuriran: 05. 2015.
English: The tablets must always be taken after the patient has fasted overnight for at least six hours and at least 30 minutes before the first food or drink of the day.
Croatian: Tablete se uvijek trebaju uzimati natašte, nakon što je bolesnik postio preko noći najmanje šest sati i najmanje 30 minuta prije prvog obroka ili pića tog dana.
English: The patient must also not lie down for one hour after taking the tablets.
Croatian: Bolesnik ne smije leći najmanje jedan sat nakon uzimanja tableta.
English: The recommended dose is one tablet taken once a day.
Croatian: Preporučena je doza jedna tableta jednom na dan.
English: Ibandronic Acid Sandoz EMA/140299/2015
Croatian: Ibandronatna kiselina Sandoz EMA/140299/2015
English: Ibandronic Acid Sandoz must be taken with a full glass of plain water (but not mineral water) while standing or sitting up, and the tablets should not be chewed, sucked or crushed.
Croatian: Ibandronatnu kiselinu Sandoz treba uzeti s punom čašom obične vode (no ne i mineralne vode) stojeći ili sjedeći, a tablete se ne smiju žvakati, cuclati niti drobiti.
English: The full EPAR for Ibandronic Acid Sandoz can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Croatian: Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Ibandronatna kiselina Sandoz vrijedi nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: Ibandronic Acid Sandoz is used to prevent ‘skeletal events' (fractures [broken bones] or bone complications requiring treatment) in patients with breast cancer and bone metastases (when the cancer has spread to the bone).
Croatian: Ibandronatna kiselina Sandoz koristi se za sprječavanje "skeletnih poremećaja" (fraktura [slomljenih kostiju] ili koštanih komplikacija koje zahtijevaju liječenje) u bolesnika s rakom dojke i metastazama u kostima (ako se rak proširio u kosti).
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Ibandronic Acid Sandoz.
Croatian: Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist izdavanja odobrenja za stavljanje lijeka u promet i svoje preporuke za uporabu lijeka Ibandronatna kiselina Sandoz HCT.
English: For more information about treatment with Ibandronic Acid Sandoz, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Croatian: Više informacija o liječenju lijekom Ibandronatna kiselina Sandoz pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
English: This means that Ibandronic Acid Sandoz is similar to a ‘reference medicine' already authorised in the European Union (EU).
Croatian: To znači da je ibandronatna kiselina Sandoz sličan „referentnom lijeku” koji je već odobren u Europskoj uniji.
English: The reduction of bone loss helps to make bones less likely to break, which is useful in preventing fractures in cancer patients with bone metastases.
Croatian: Snižavanjem gubitka kosti doprinosi se rjeđim slučajevima prijeloma kostiju što je korisno za sprječavanje fraktura u bolesnika s rakom i metastazama u kostima.
English: The European Commission granted a marketing authorisation valid throughout the EU for Ibandronic Acid Sandoz on 26 July 2011.
Croatian: Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Ibandronatna kiselina Sandoz na snazi u Europskoj uniji od 26. srpnja 2011.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Ibandronic Acid Sandoz, including the appropriate precautions to be followed by healthcare professionals and patients.
Croatian: Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi za lijek Ibandronatna kiselina Sandoz nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
English: Because Ibandronic Acid Sandoz is a generic medicine and is bioequivalent to the reference medicine, its benefits and risks are taken as being the same as the reference medicine's.
Croatian: Budući da je Ibandronatna kiselina Sandoz generički lijek te je bioekvivalentan referentnom lijeku, smatra se da su njegove koristi i rizici isti kao i oni referentnog lijeka.
English: It stops the action of osteoclasts, the cells in the body that are involved in breaking down the bone tissue.
Croatian: Blokira aktivnost osteoklasta, stanica u tijelu koje su uključene u razgradnju koštanog tkiva, što rezultira manjim gubitkom kosti.
English: This document is a summary of the European public assessment report (EPAR) for Ibandronic Acid Sandoz.
Croatian: Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Ibandronatna kiselina Sandoz.
English: Because Ibandronic Acid Sandoz is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine.
Croatian: Budući da je Ibandronatna kiselina Sandoz generički lijek, ispitivanja na bolesnicima bila su ograničena na utvrđivanje činjenice je li riječ o bioekvivalentu referentnom lijeku.
English: What measures are being taken to ensure the safe and effective use of Ibandronic Acid Sandoz?
Croatian: Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Ibandronatna kiselina Sandoz?
English: The CHMP concluded that, in accordance with EU requirements, Ibandronic Acid Sandoz has been shown to have comparable quality and to be bioequivalent to Bondronat.
Croatian: Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji zaključio je da je u skladu sa zahtjevima EU-a potvrđeno kako lijek Ibandronatna kiselina Sandoz posjeduje usporedivu kvalitetu te je bioekvivalentan s lijekom Bondronat.
English: A risk management plan has been developed to ensure that Ibandronic Acid Sandoz is used as safely as possible.
Croatian: Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Ibandronatna kiselina Sandoz.
English: Ibandronic Acid Sandoz is a ‘generic medicine'.
Croatian: Ibandronatna kiselina Sandoz je „generički lijek”.
English: The active substance in Ibandronic Acid Sandoz, ibandronic acid, is a bisphosphonate.
Croatian: Djelatna tvar u lijeku Ibandronatna kiselina Sandoz, ibandronatna kiselina, je bisfosfonat.
English: What are the benefits and risks of Ibandronic Acid Sandoz?
Croatian: Koje su koristi i rizici od lijeka Ibandronatna kiselina Sandoz?
English: The Committee recommended that Ibandronic Acid Sandoz be given marketing authorisation.
Croatian: Odbor je preporučio izdavanje odobrenja za stavljanje u promet lijeka Ibandronatna kiselina Sandoz.
English: Ibandronic Acid Sandoz ibandronic acid
Croatian: Ibandronatna kiselina Sandoz ibandronatna kiselina
English: The reference medicine for Ibandronic Acid Sandoz is Bondronat.
Croatian: Referentni lijek za ibandronatnu kiselinu Sandoz je Bondronat.
English: Ibandronic Acid Sandoz is a medicine that contains the active substance ibandronic acid.
Croatian: Ibandronatna kiselina Sandoz je lijek koji sadrži ibandronatnu kiselinu kao djelatnu tvar.
English: Why has Ibandronic Acid Sandoz been approved?
Croatian: Zašto je lijek Ibandronatna kiselina Sandoz odobren?
English: Other information about Ibandronic Acid Sandoz:
Croatian: Ostale informacije o lijeku Ibandronatna kiselina Sandoz
English: What is Ibandronic Acid Sandoz?
Croatian: Što je Ibandronatna kiselina Sandoz?
English: What is Ibandronic Acid Sandoz used for?
Croatian: Za što se Ibandronatna kiselina Sandoz koristi?
English: How is Ibandronic Acid Sandoz used?
Croatian: Kako se Ibandronatna kiselina Sandoz koristi?